Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping

References

• Banerjee, A. and Tsiatis, A. A. (2006). Adaptive Two-Stage Designs in Phase II Clinical Trials, Statistics in Medicine 25: 3382–3395.
   PubMed Web of Science ®Google Scholar
• Berry, D. A. (2011). Adaptive Clinical Trials: The Promise and the Caution, Journal of Clinical Oncology 29: 606–609.
   PubMed Web of Science ®Google Scholar
• Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D’Amato, G. Z., Blay, J.-Y. Y., Mita, M. M., Sankhala, K. K., Berk, L., Rivera, V. M., Clackson, T., Loewy, J. W., Haluska, F. G., and Demetri, G. D. (2012). Phase II Study of the Mammalian Target of RAPAMYCIN Inhibitor Ridaforolimus in Patients with Advanced Bone and Soft Tissue Sarcomas, Journal of Clinical Oncology 30: 78–84.
   PubMed Web of Science ®Google Scholar
• Chow, S.-C. C. and Chang, M. (2008). Adaptive Design Methods in Clinical Trials – A Review. Orphanet Journal of Rare Diseases 3: 11.
   PubMed Web of Science ®Google Scholar
• Englert, S. and Kieser, M. (2013). Optimal Adaptive Two-Stage Designs for Phase II Cancer Clinical Trials, Biometrical Journal 55: 955–968.
   PubMed Web of Science ®Google Scholar
• Katz, P. O., Gerson, L. B., and Vela, M. F. (2013). Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease, American Journal of Gastroenterology 108: 308-328.
   Web of Science ®Google Scholar
• Koon, H. B., Krown, S. E., Lee, J. Y., Honda, K., Rapisuwon, S., Wang, Z., Aboulafia, D., Reid, E. G., Rudek, M. A., Dezube, B. J., and Noy, A. (2014). Phase II Trial of Imatinib in AIDS-Associated Kaposi’s Sarcoma: AIDS Malignancy Consortium Protocol 042. Journal of Clinical Oncology 32: 402–408.
   PubMed Web of Science ®Google Scholar
• Kwak, M. and Jung, S.-H. H. (2014). Phase II Clinical Trials with Time-to-Event Endpoints: Optimal Two-Stage Designs with One-Sample Log-Rank Test, Statistics in Medicine 33: 2004–2016.
   PubMed Web of Science ®Google Scholar
• Lin, Y. and Shih, W. J. (2004). Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials, Biometrics 60: 482–490.
   PubMed Web of Science ®Google Scholar
• Noy, A., Scadden, D. T., Lee, J., Dezube, B. J., Aboulafia, D., Tulpule, A., Walmsley, S., and Gill, P. (2005). Angiogenesis Inhibitor IM862 Is Ineffective against AIDS-Kaposi’s Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team, Journal of Clinical Oncology 23: 990–998.
   PubMed Web of Science ®Google Scholar
• Shan, G. (2018a). Exact Confidence Limits for the Probability of Response in Two-Stage Designs, Statistics 52: 1086–1095.
   PubMed Web of Science ®Google Scholar
• Shan, G. (2018b). Exact Confidence Limits for the Response Rate in Two-Stage Designs with Over- or Under-enrollment in the Second Stage, Statistical Methods in Medical Research 27: 1045–1055.
   PubMed Web of Science ®Google Scholar
• Shan, G., Hutson, A. D., and Wilding, G. E. (2012). Two-Stage k-Sample Designs for the Ordered Alternative Problem, Pharmaceutical Statistics 11: 287–294.
   PubMed Web of Science ®Google Scholar
• Shan, G. and Ma, C. (2016). Unconditional Tests for Comparing Two Ordered Multinomials, Statistical Methods in Medical Research 25: 241–254.
   PubMed Web of Science ®Google Scholar
• Shan, G., Wilding, G. E., Hutson, A. D., and Gerstenberger, S. (2016). Optimal Adaptive Two-Stage Designs for Early Phase II Clinical Trials, Statistics in Medicine 35: 1257–1266.
   PubMed Web of Science ®Google Scholar
• Shan, G., Zhang, H., and Jiang, T. (2016). Minimax and Admissible Adaptive Two-Stage Designs in Phase II Clinical Trials, BMC Medical Research Methodology 16: 90.
   Google Scholar
• Shan, G., Zhang, H., and Jiang, T. (2017). Efficient confidence Limits for Adaptive One-Arm Two-Stage Clinical Trials with Binary Endpoints, BMC Medical Research Methodology 17: 22.
   Google Scholar
• Simon, R. (1989). Optimal Two-Stage Designs for Phase II Clinical Trials, Controlled Clinical Trials 10: 1–10.
   PubMedGoogle Scholar
• Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., and Gwyther, S. G. (2000). New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, Journal of National Cancer Institute 92: 205–216.
   PubMed Web of Science ®Google Scholar
• Trippa, L., Lee, E. Q., Wen, P. Y., Batchelor, T. T., Cloughesy, T., Parmigiani, G., and Alexander, B. M. (2012). Bayesian Adaptive Randomized Trial Design for Patients with Recurrent Glioblastoma, Journal of Clinical Oncology 30: 3258–3263.
   PubMed Web of Science ®Google Scholar
• U. S. Food and Drug Administration. (2010). Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics.
   Google Scholar
• Wilding, G. E., Shan, G., and Hutson, A. D. (2012). Exact Two-Stage Designs for Phase II Activity Trials with Rank-Based Endpoints, Contemporary Clinical Trials 33: 332–341.
   PubMed Web of Science ®Google Scholar
• Wolsey, L. A. (1998). Integer Programming, New York: Wiley.
   Google Scholar
• Zhang, H. and Shan, G. (2019). Letter to the Editor: A Novel Confidence Interval for a Single Proportion in the Presence of Clustered Binary Outcome Data (SMMR, 2019), Statistical Methods in Medical Research.
   Google Scholar
• Zheng, L., Rosenkranz, S. L., Taiwo, B., Para, M. F., Eron, J. J., and Hughes, M. D. (2012). The Design of Single-Arm Clinical Trials of Combination Antiretroviral Regimens for Treatment-Naive HIV-Infected Patients, AIDS Research and Human Retroviruses 29: 652–657.
   Web of Science ®Google Scholar